{"id":640829,"date":"2023-03-01T21:14:03","date_gmt":"2023-03-01T21:14:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=640829"},"modified":"2023-03-01T21:14:03","modified_gmt":"2023-03-01T21:14:03","slug":"becker-muscular-dystrophy-market-is-projected-to-grow-during-the-forecast-period-20222032-estimates-delveinsight-key-companies-immunoforge-italfarmaco-reveragen-edgewise-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/becker-muscular-dystrophy-market-is-projected-to-grow-during-the-forecast-period-20222032-estimates-delveinsight-key-companies-immunoforge-italfarmaco-reveragen-edgewise-therapeutics_640829.html","title":{"rendered":"Becker Muscular Dystrophy Market is Projected to Grow During the Forecast Period (2022-2032) – Estimates DelveInsight | Key Companies – ImmunoForge, Italfarmaco, ReveraGen, Edgewise Therapeutics"},"content":{"rendered":"
\n
\"Becker<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Becker Muscular Dystrophy market is set to evolve immensely in the coming years due to the rising awareness of the disease and incremental healthcare spending worldwide, which would expand the market size to enable drug manufacturers to penetrate more into the market.<\/div>\n

The pharmaceutical giants and academics are working to assess challenges and seek opportunities that could influence Becker Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/em><\/p>\n

DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Becker Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Becker Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Becker<\/p>\n

Becker Muscular Dystrophy: An Overview<\/strong><\/p>\n

Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder resulting in progressive deterioration of limbs and cardiac and skeletal muscle deterioration. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). BMD usually begins in teens or early adulthood, and the course is slower and far less predictable than that of DMD.<\/p>\n

Early symptoms of BMD are cramps after exercising, and later in life, the person begins to experience problems while walking quickly or running. Other noticeable symptoms besides weakness are falling, feeling “worn out,” and changes in the skeletal system. Muscle weakness often affects the legs and pelvis and slowly gets worse. Few affected individuals even have learning problems, but these cases are typically minor.<\/p>\n

Becker Muscular Dystrophy Market Key Facts<\/strong><\/p>\n